Type I interferons as vaccine adjuvants against infectious diseases and cancer

References

• Edelman R. Vaccine adjuvants. Rev. Infect. Dis.2(3), 370–383 (1980).
   PubMedGoogle Scholar
• Singh M, O’Hagan D. Advances in vaccine adjuvants. Nat. Biotechnol.17(11), 1075–1081 (1999).
   PubMed Web of Science ®Google Scholar
• Aguilar JC, Rodriguez EG. Vaccine adjuvants revisited. Vaccine25(19), 3752–3762 (2007).
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol.5(10), 987–995 (2004).
   PubMed Web of Science ®Google Scholar
• Lin R, Tarr PE, Jones TC. Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases. Clin. Infect. Dis.21(6), 1439–1449 (1995).
   Google Scholar
• Chelbi-Alix MK, Wietzerbin J. Interferon, a growing cytokine family: 50 years of interferon research. Biochimie89(6–7), 713–778 (2007).
   PubMed Web of Science ®Google Scholar
• Belardelli F, Vignaux F, Proietti E, Gresser I. Injection of mice with antibody to interferon renders peritoneal macrophages permissive for vesicular stomatitis virus and encephalomyocarditis virus. Proc. Natl Acad. Sci. USA81(2), 602–606 (1984).
   Google Scholar
• Brassard DL, Grace MJ and Bordens RW. Interferon-α as an immunotherapeutic protein. J. Leukoc. Biol.71(4), 565–581 (2002).
   PubMed Web of Science ®Google Scholar
• Bekisz J, Schmeisser H, Hernandez J, Goldman ND, Zoon KC. Human interferons α, β and ω. Growth Factors22(4), 243–251 (2004).
   PubMed Web of Science ®Google Scholar
• Biron CA. Role of early cytokines, including α and β interferons (IFN-α/β), in innate and adaptive immune responses to viral infections. Semin. Immunol.10(5), 383–390 (1998).
   PubMed Web of Science ®Google Scholar
• Biron CA. Interferons a and b as immune regulators – a new look. Immunity14(6), 661–664 (2001).
   PubMed Web of Science ®Google Scholar
• Belardelli F, Gresser I. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol. Today17(8), 369–372 (1996).
   PubMedGoogle Scholar
• Le Bon A, Etchart N, Rossmann C et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat. Immunol.4(10), 1009–1015 (2003).
   PubMed Web of Science ®Google Scholar
• Wenner CA, Guler ML, Macatonia SE, O’Garra A, Murphy KM. Roles of IFN-γ and IFN-α in IL-12-induced T helper cell-1 development. J. Immunol.156(4), 1442–1447 (1996).
   PubMed Web of Science ®Google Scholar
• Yates A, Bergmann C, Van Hemmen JL, Stark J, Callard R. Cytokine-modulated regulation of helper T cell populations. J. Theor. Biol.206(4), 539–560 (2000).
   PubMed Web of Science ®Google Scholar
• Le Bon A, Schiavoni G, D’Agostino G, Gresser I, Belardelli F, Tough DF. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity14(4), 461–470 (2001).
   PubMed Web of Science ®Google Scholar
• Proietti E, Bracci L, Puzelli S et al. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J. Immunol.169(1), 375–383 (2002).
   PubMed Web of Science ®Google Scholar
• So EY, Park HH, Lee CE. IFN-γ and IFN-α posttranscriptionally down-regulate the IL-4-induced IL-4 receptor gene expression. J. Immunol.165(10), 5472–5479 (2000).
   PubMedGoogle Scholar
• Ishikawa R, Biron CA. IFN induction and associated changes in splenic leukocyte distribution. J. Immunol.150(9), 3713–3727 (1993).
   Google Scholar
• Fitzgerald-Bocarsly P, Feng D. The role of type I interferon production by dendritic cells in host defense. Biochimie89(6–7), 843–855 (2007).
   PubMed Web of Science ®Google Scholar
• Santini SM, Lapenta C, Logozzi M et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J. Exp. Med.191(10), 1777–1788 (2000).
   PubMed Web of Science ®Google Scholar
• Honda K, Sakaguchi S, Nakajima C et al. Selective contribution of IFN-α/β signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection. Proc. Natl Acad. Sci. USA100(19), 10872–10877 (2003).
   PubMed Web of Science ®Google Scholar
• Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med.5(11), 1249–1255 (1999).
   PubMed Web of Science ®Google Scholar
• Luft T, Pang KC, Thomas E et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J. Immunol.161(4), 1947–1953 (1998).
   PubMed Web of Science ®Google Scholar
• Uematsu S, Akira S. Toll-like receptors and type I interferons. J. Biol. Chem.282(21), 15319–15323 (2007).
   PubMed Web of Science ®Google Scholar
• Guy B. The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol.5(7), 505–517 (2007).
   PubMed Web of Science ®Google Scholar
• Siren J, Pirhonen J, Julkunen I, Matikainen S. IFN-α regulates TLR-dependent gene expression of IFN-α, IFN-β, IL-28, and IL-29. J. Immunol.174(4), 1932–1937 (2005).
   PubMedGoogle Scholar
• Lore K, Betts MR, Brenchley JM et al. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. J. Immunol.171(8), 4320–4328 (2003).
   PubMed Web of Science ®Google Scholar
• Fujimoto C, Nakagawa Y, Ohara K, Takahashi H. Polyriboinosinic polyribocytidylic acid [poly(I:C)]/TLR3 signaling allows class I processing of exogenous protein and induction of HIV-specific CD8+ cytotoxic T lymphocytes. Int. Immunol.16(1), 55–63 (2004).
   PubMed Web of Science ®Google Scholar
• Mattei F, Schiavoni G, Belardelli F, Tough DF. IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation. J. Immunol.167(3), 1179–1187 (2001).
   PubMed Web of Science ®Google Scholar
• Salem ML, Kadima AN, Cole DJ, Gillanders WE. Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J. Immunother (1997).28(3), 220–228 (2005).
   PubMed Web of Science ®Google Scholar
• Salem ML, El-Naggar SA, Kadima A, Gillanders WE, Cole DJ. The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. Vaccine24(24), 5119–5132 (2006).
   PubMed Web of Science ®Google Scholar
• Durand V, Wong SY, Tough DF, Le Bon A. Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-α/β. Immunol. Cell Biol.82(6), 596–602 (2004).
   PubMed Web of Science ®Google Scholar
• McBride S, Hoebe K, Georgel P, Janssen E. Cell-associated double-stranded RNA enhances antitumor activity through the production of type I IFN. J. Immunol.177(9), 6122–6128 (2006).
   PubMedGoogle Scholar
• Yoneyama M, Kikuchi M, Natsukawa T et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol.5(7), 730–737 (2004).
   PubMed Web of Science ®Google Scholar
• Yoneyama M, Kikuchi M, Matsumoto K et al. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J. Immunol.175(5), 2851–2858 (2005).
   PubMed Web of Science ®Google Scholar
• Kang DC, Gopalkrishnan RV, Wu Q, Jankowsky E, Pyle AM, Fisher PB. Mda-5: an interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc. Natl Acad. Sci. USA99(2), 637–642 (2002).
   PubMed Web of Science ®Google Scholar
• Gitlin L, Barchet W, Gilfillan S et al. Essential role of Mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc. Natl Acad. Sci. USA103(22), 8459–8464 (2006).
   PubMed Web of Science ®Google Scholar
• Kornbluth RS, Stone GW. Immunostimulatory combinations: designing the next generation of vaccine adjuvants. J. Leukoc. Biol.80(5), 1084–1102 (2006).
   PubMedGoogle Scholar
• Doyle S, Vaidya S, O’Connell R et al. IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity17(3), 251–263 (2002).
   PubMed Web of Science ®Google Scholar
• Hertzog PJ, O’Neill LA, Hamilton JA. The interferon in TLR signaling: more than just antiviral. Trends Immunol.24(10), 534–539 (2003).
   PubMed Web of Science ®Google Scholar
• Hamilton JA, Whitty GA, Kola I, Hertzog PJ. Endogenous IFN-α/β suppresses colony-stimulating factor (CSF)-1-stimulated macrophage DNA synthesis and mediates inhibitory effects of lipopolysaccharide and TNF-α. J. Immunol.156(7), 2553–2557 (1996).
   PubMed Web of Science ®Google Scholar
• Heil F, Hemmi H, Hochrein H et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science303(5663), 1526–1529 (2004).
   PubMed Web of Science ®Google Scholar
• Gorden KB, Gorski KS, Gibson SJ et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J. Immunol.174(3), 1259–1268 (2005).
   PubMed Web of Science ®Google Scholar
• Wagner TL, Ahonen CL, Couture AM et al. Modulation of Th1 and Th2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell. Immunol.191(1), 10–19 (1999).
   PubMed Web of Science ®Google Scholar
• Vasilakos JP, Smith RM, Gibson SJ et al. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell. Immunol.204(1), 64–74 (2000).
   PubMed Web of Science ®Google Scholar
• Wille-Reece U, Flynn BJ, Lore K et al. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc. Natl Acad. Sci. USA102(42), 15190–15194 (2005).
   PubMed Web of Science ®Google Scholar
• Tokunaga T, Yamamoto H, Shimada S et al. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J. Natl. Cancer Inst.72(4), 955–962 (1984).
   PubMed Web of Science ®Google Scholar
• Cho HJ, Hayashi T, Datta SK et al. IFN-α/β promote priming of antigen-specific CD8+ and CD4+ T lymphocytes by immunostimulatory DNA-based vaccines. J. Immunol.168(10), 4907–4913 (2002).
   PubMed Web of Science ®Google Scholar
• Wakita D, Chamoto K, Zhang Y et al. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen. Int. Immunol.18(3), 425–434 (2006).
   PubMed Web of Science ®Google Scholar
• Takaoka A, Wang Z, Choi MK et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature448(7152), 501–505 (2007).
   PubMed Web of Science ®Google Scholar
• Bramson JL, Dayball K, Hall JR et al. Super-activated interferon-regulatory factors can enhance plasmid immunization. Vaccine21(13–14), 1363–1370 (2003).
   PubMed Web of Science ®Google Scholar
• Sato M, Suemori H, Hata N et al. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-α/β gene induction. Immunity13(4), 539–548 (2000).
   PubMed Web of Science ®Google Scholar
• Sasaki S, Amara RR, Yeow WS, Pitha PM, Robinson HL. Regulation of DNA-raised immune responses by cotransfected interferon regulatory factors. J. Virol.76(13), 6652–6659 (2002).
   PubMedGoogle Scholar
• Ferrantini M, Belardelli F. Gene therapy of cancer with interferon: lessons from tumor models and perspectives for clinical applications. Semin. Cancer Biol.10(2), 145–157 (2000).
   PubMed Web of Science ®Google Scholar
• Tovey MG, Lallemand C, Meritet JF, Maury C. Adjuvant activity of interferon a: mechanism(s) of action. Vaccine24(Suppl. 2), 46–47 (2006).
   Google Scholar
• Cheng G, Zhao X, Yan W et al. α interferon is a powerful adjuvant for a recombinant protein vaccine against foot-and-mouth disease virus in swine, and an effective stimulus of in vivo immune response. Vaccine25(28), 5199–5208 (2007).
   PubMed Web of Science ®Google Scholar
• Cull VS, Broomfield S, Bartlett EJ, Brekalo NL, James CM. Coimmunisation with type I IFN genes enhances protective immunity against cytomegalovirus and myocarditis in gB DNA-vaccinated mice. Gene Ther.9(20), 1369–1378 (2002).
   PubMed Web of Science ®Google Scholar
• Potebnya GP, Kudryavets YY, Lisovenko GS et al. Experimental study of the efficacy of combined use of cancer vaccine and interferon. Exp. Oncol.29(2), 102–105 (2007).
   Google Scholar
• Prell RA, Li B, Lin JM, VanRoey M, Jooss K. Administration of IFN-α enhances the efficacy of a granulocyte macrophage colony stimulating factor-secreting tumor cell Vaccine Cancer Res.65(6), 2449–2456 (2005).
   PubMed Web of Science ®Google Scholar
• Grob PJ, Joller-Jemelka HI, Binswanger U, Zaruba K, Descoeudres C, Fernex M. Interferon as an adjuvant for hepatitis B vaccination in non- and low-responder populations. Eur. J. Clin. Microbiol.3(3), 195–198 (1984).
   PubMedGoogle Scholar
• Goldwater PN. Randomized comparative trial of Interferon-α versus placebo in hepatitis B vaccine non-responders and hyporesponders. Vaccine12(5), 410–414 (1994).
   PubMed Web of Science ®Google Scholar
• Rizza P, Capone I, Urbani F et al. Evaluation of the effects of human leukocyte IFN-α on the immune response to the HBV vaccine in healthy unvaccinated individuals. Vaccine26(8), 1038–1049 (2008).
   PubMed Web of Science ®Google Scholar
• Di Pucchio T, Pilla L, Capone I et al. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-α results in the activation of specific CD8+ T cells and monocyte/dendritic cell precursors. Cancer Res.66(9), 4943–4951 (2006).
   PubMed Web of Science ®Google Scholar
• Mowat AM. Anatomical basis of tolerance and immunity to intestinal antigens. Nat. Rev. Immunol.3(4), 331–341 (2003).
   PubMed Web of Science ®Google Scholar
• De Magistris MT. Mucosal delivery of vaccine antigens and its advantages in pediatrics. Adv. Drug Deliv. Rev.58(1), 52–67 (2006).
   PubMed Web of Science ®Google Scholar
• Freytag LC, Clements JD. Mucosal adjuvants. Vaccine23(15), 1804–1813 (2005).
   PubMed Web of Science ®Google Scholar
• Meritet JF, Maury C, Tovey MG. Effect of oromucosal administration of IFN-α on allergic sensitization and the hypersensitive inflammatory response in animals sensitized to ragweed pollen. J. Interferon Cytokine Res.21(8), 583–593 (2001).
   PubMed Web of Science ®Google Scholar
• Bracci L, Canini I, Puzelli S et al. Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level. Vaccine23(23), 2994–3004 (2005).
   PubMed Web of Science ®Google Scholar
• Gresser I. The antitumor effects of interferon: a personal history. Biochimie89(6–7), 723–728 (2007).
   PubMed Web of Science ®Google Scholar
• Brodeur BR, Merigan TC. Suppressive effect of interferon on the humoral immune response to sheep red blood cells in mice. J. Immunol.113(4), 1319–1325 (1974).
   PubMed Web of Science ®Google Scholar
• Farrar JD, Smith JD, Murphy TL, Leung S, Stark GR, Murphy KM. Selective loss of type I interferon-induced STAT4 activation caused by a minisatellite insertion in mouse Stat2. Nat. Immunol.1(1), 65–69 (2000).
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Chiocchia G. Dendritic cells and interferon-mediated autoimmunity. Biochimie89(6–7), 856–871 (2007).
   Google Scholar
• Gilboa E. DC-based cancer vaccines. J. Clin. Invest.117(5), 1195–1203 (2007).
   PubMed Web of Science ®Google Scholar